These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2804191)

  • 41. Galvanic skin responses (GSR) and plethysmographic changes induced by chlorimipramine, imipramine and placebo.
    Lapierre YD
    Curr Ther Res Clin Exp; 1974 May; 16(5):461-9. PubMed ID: 4209521
    [No Abstract]   [Full Text] [Related]  

  • 42. Diazepam suppresses the acquisition but not the expression of 'fear-potentiation' of the acoustic startle response in man.
    Scaife JC; Langley RW; Bradshaw CM; Szabadi E
    J Psychopharmacol; 2005 Jul; 19(4):347-56. PubMed ID: 15982989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder.
    Pato MT; Zohar-Kadouch R; Zohar J; Murphy DL
    Am J Psychiatry; 1988 Dec; 145(12):1521-5. PubMed ID: 3057923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of ketanserin and haloperidol on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man.
    Graham SJ; Langley RW; Balboa VA; Bradshaw CM; Szabadi E
    J Psychopharmacol; 2002 Mar; 16(1):15-22. PubMed ID: 11949767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet 3H-imipramine binding sites in obsessive-compulsive behavior.
    Kim SW; Dysken MW; Pandey GN; Davis JM
    Biol Psychiatry; 1991 Sep; 30(5):467-74. PubMed ID: 1657222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autonomic activity in relation to cerebrospinal fluid neurochemistry in obsessive and disruptive children and adolescents.
    Zahn TP; Kruesi MJ; Swedo SE; Leonard HL; Rapoport JL
    Psychophysiology; 1996 Nov; 33(6):731-9. PubMed ID: 8961795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo.
    Flaten MA; Simonsen T; Zahlsen K; Aamo T; Sager G; Olsen H
    Psychopharmacology (Berl); 2004 Nov; 176(3-4):426-34. PubMed ID: 15549277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
    DeVeaugh-Geiss J; Moroz G; Biederman J; Cantwell D; Fontaine R; Greist JH; Reichler R; Katz R; Landau P
    J Am Acad Child Adolesc Psychiatry; 1992 Jan; 31(1):45-9. PubMed ID: 1537780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive and psychophysiological correlates of disgust in obsessive-compulsive disorder.
    Whitton AE; Henry JD; Grisham JR
    Br J Clin Psychol; 2015 Mar; 54(1):16-33. PubMed ID: 24916162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine.
    Zahn TP; Pickar D
    Biol Psychiatry; 1993 Jul 1-15; 34(1-2):3-12. PubMed ID: 8104043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autonomic activity in relation to symptom ratings and reaction time in unmedicated patients with schizophrenia.
    Zahn TP; Pickar D
    Schizophr Res; 2005 Nov; 79(2-3):257-70. PubMed ID: 16006104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute cardiovascular responses to arousal from non-REM sleep during normoxia and hypoxia.
    Catcheside PG; Chiong SC; Orr RS; Mercer J; Saunders NA; McEvoy RD
    Sleep; 2001 Dec; 24(8):895-902. PubMed ID: 11766159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antidepressants as a prophylaxis against depression in the obsessive compulsive person.
    Cammer L
    Psychosomatics; 1973; 14(4):201-6. PubMed ID: 4794866
    [No Abstract]   [Full Text] [Related]  

  • 56. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacotherapy of obsessive-compulsive disorder.
    Jermain DM; Crismon ML
    Pharmacotherapy; 1990; 10(3):175-98. PubMed ID: 2196535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats.
    Cassella JV; Davis M
    Psychopharmacology (Berl); 1985; 87(3):278-82. PubMed ID: 3936082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of haloperidol and clozapine on prepulse inhibition of the acoustic startle response and the N1/P2 auditory evoked potential in man.
    Graham SJ; Langley RW; Bradshaw CM; Szabadi E
    J Psychopharmacol; 2001 Dec; 15(4):243-50. PubMed ID: 11769817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.